# Survival with primary lung cancer in Northern Ireland: 1991–1992

## TL;DR

This study analyzed lung cancer survival in Northern Ireland from 1991–1992, finding poor overall survival and highlighting the impact of treatment and patient characteristics.

## Contribution

The first population-based study of lung cancer survival in Northern Ireland, identifying treatment effects and patient factors.

## Key findings

- 1-year survival was 24.5% with a median survival of 4.7 months.
- Surgical patients had the best 1-year survival (76.8%), but part of this benefit was due to case-mix factors.
- A screening test revealed 210 patients were misclassified, showing a gap between model predictions and actual treatment decisions.

## Abstract

Lung cancer is a major cause of death in Western countries, but survival had never been studied in Northern Ireland (NI) on a population basis prior to this study.

The primary aims were to describe the survival of patients with primary lung cancer, evaluate the effect of treatment, identify patient characteristics influencing survival and treatment and describe current trends in survival.

A population-based study identified all incident cases of primary lung cancer in NI during 1991–2 and followed them for 21 months. Their clinical notes were traced and relevant details abstracted. Survival status was monitored via the Registrar General’s Office, and ascertainment is thought to be near-complete. Appropriate statistical methods were used to analyse the survival data.

Some 855 incident cases were studied. Their 1-year survival was 24.5% with a median survival time of 4.7 months. Surgical patients had the best 1-year survival, 76.8%; however, adjustment suggested that about half of the benefit could be attributed to case-mix factors. Factors influencing treatment allocation were also identified, and a screening test showed the discordance between ‘model’ and ‘medic’: 210 patients were misclassified. Finally, the current trend in 1-year survival observed in the Republic of Ireland was best in the British Isles.

Overall, survival remains poor. The better survival of surgical patients is due, in part, to their superior case-mix profiles. Survival with other therapies is less good suggesting that the criteria for treatment might be relaxed with advantage using a treatment model to aid decision-making.